COMPANY

CellCentric

HQ: Burlington, MA (US office) source · cellcentric.com ↗

Keywords: small molecule oncology multiple myeloma cancer Multiple Myeloma Refractory Multiple Myeloma in Relapse Metastatic Castration-Resistant Prostate Cancer Metastatic Breast Cancer Non-small Cell Lung Cancer Haematological Malignancy Acute Myeloid Leukemia Non Hodgkin Lymphoma Higher-risk Myelodysplastic Syndrome Peripheral T Cell Lymphoma CCS1477

Location: Burlington, MA (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Raises and deals from press releases

Raise Series C · $120M · announced May 19, 2025 Company release ↗
Source quote
- May 19, 2025 · Company release ↗
  “Cambridge, UK and Boston, MA – May 19, 2025 – CellCentric, a clinical-stage biotechnology company developing inobrodib, a first in class oral cancer drug to treat specific cancers, notably multiple myeloma, today announced the completion of a $120 million Series C funding round”

Raises announced in these releases: $120M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Jan 22, 2026 Trial start Phase 2: Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma source ↗
May 19, 2025 Raise Series C · $120M source ↗
Aug 9, 2019 Trial start Phase 1/Phase 2: Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies source ↗
Jul 23, 2018 Trial start Phase 1/Phase 2: Study to Evaluate CCS1477 in Advanced Tumours source ↗
2026-08 Trial start Phase 3: Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma source ↗

Upcoming milestones

Mar 31, 2027 (ESTIMATED) · Phase 1/Phase 2 · Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies · NCT04068597
2029-11 (ESTIMATED) · Phase 3 · Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma · NCT07772024
Dec 1, 2029 (ESTIMATED) · Phase 2 · Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · NCT07096778

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT03568656	Study to Evaluate CCS1477 in Advanced Tumours	Phase 1/Phase 2	Completed	Jul 23, 2018	Jul 6, 2025 (actual)
NCT07096778	Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma	Phase 2	Recruiting	Jan 22, 2026	Dec 1, 2029 (estimated)
NCT07772024	Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma	Phase 3	Recruiting	2026-08	2029-11 (estimated)
NCT04068597	Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies	Phase 1/Phase 2	Recruiting	Aug 9, 2019	Mar 31, 2027 (estimated)